Abstract
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
| Original language | English |
|---|---|
| Pages (from-to) | 262-267 |
| Number of pages | 6 |
| Journal | Diabetes and Metabolism Journal |
| Volume | 36 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Fatty acid oxidation
- Glucagon-like peptide 1
- Non-alcoholic fatty liver disease
Fingerprint
Dive into the research topics of 'GLP-1 receptor agonist and non-alcoholic fatty liver disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver